Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, Berindan-Neagoe I. Braicu C, et al. Among authors: eniu a. J Exp Clin Cancer Res. 2018 Oct 20;37(1):257. doi: 10.1186/s13046-018-0920-2. J Exp Clin Cancer Res. 2018. PMID: 30342533 Free PMC article.
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients.
Vidra R, Ciuleanu TE, Nemeș A, Pascu O, Heroiu AM, Antone N, Vidrean AI, Oprean CM, Pop LA, Berindan-Neagoe I, Eniu R, Eniu A. Vidra R, et al. Among authors: eniu a. Int J Environ Res Public Health. 2022 Apr 4;19(7):4314. doi: 10.3390/ijerph19074314. Int J Environ Res Public Health. 2022. PMID: 35409996 Free PMC article.
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.
Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, Bertolini F. Bouche G, et al. Among authors: eniu a. Ecancermedicalscience. 2014 Sep 9;8:463. doi: 10.3332/ecancer.2014.463. eCollection 2014. Ecancermedicalscience. 2014. PMID: 25228919 Free PMC article.
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel R. Ciardiello F, et al. Among authors: eniu a. Ann Oncol. 2014 Sep;25(9):1673-1678. doi: 10.1093/annonc/mdu217. Epub 2014 Jun 20. Ann Oncol. 2014. PMID: 24950979 Free article. No abstract available.
PARP Inhibitors in Breast Cancer: Why, How, and When?
Paradiso A, Andreopoulou E, Conte P, Eniu A, Saghatchian M. Paradiso A, et al. Among authors: eniu a. Breast Care (Basel). 2018 Jul;13(3):216-219. doi: 10.1159/000490746. Epub 2018 Jun 20. Breast Care (Basel). 2018. PMID: 30069183 Free PMC article. No abstract available.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators. Zielinski C, et al. Among authors: eniu a. Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5. Lancet Oncol. 2016. PMID: 27501767 Clinical Trial.
102 results